Market Place
Sourcing Support
BeyondSpring Presents Phase 2 Efficacy of Pembrolizumab Combo
11 Nov 2024 //
GLOBENEWSWIRE
FDA Approves Novocure’s Optune Lua® For Lung Cancer Treatment
15 Oct 2024 //
BUSINESSWIRE
BeyondSpring Presents DUBLIN-3 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Veracyte`s Test Predicts Chemo Benefit In Metastatic Prostate Cancer
15 Sep 2024 //
BUSINESSWIRE
BeyondSpring Presents Plinabulin Phase 3 Data At ISLAC 2024
10 Sep 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of June 19, 2024
19 Jun 2024 //
FDA
Sagent Pharma: Docetaxel Injection Recall For Particulate Matter
28 May 2024 //
PR NEWSWIRE
Theratechnologies Sudocetaxel Data: Efficacy Safety In Solids At Asco24
23 May 2024 //
GLOBENEWSWIRE
Theratechnologies: TH1902 Long-Term Solid Tumor Data At ASCO 2024
02 May 2024 //
GLOBENEWSWIRE
Matinas Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel
25 Mar 2024 //
GLOBENEWSWIRE
Venus Remedies secures marketing approval for two oncology drugs
30 Dec 2023 //
INDIAN PHARMA POST
Polaris Initiates Ph 3 Trial: First Patient Dosed with ADI-PEG 20/Placebo
04 Dec 2023 //
GLOBENEWSWIRE
PDS Biotech Announces Immune Response Data from Ph 1/2 Trial Evaluating PDS0301
11 Oct 2023 //
GLOBENEWSWIRE
Zanidatamab Plus Docetaxel Yields safety in Advanced HER2+ Breast Cancer
22 Aug 2023 //
ONCLIVE
PDS Bio Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel
17 Jul 2023 //
GLOBENEWSWIRE
Intas Pharmaceuticals Limited on FDA Import Alert List
06 Jun 2023 //
FDA
Venus Remedies gets marketing authorization for Docetaxel
01 Jun 2023 //
ECONOMIC TIMES
Mylan`s Generic Docetaxel Receives Receives Approval in the U.S.
11 May 2023 //
FDA
Darolutamide approved for additional prostate cancer indication in China
21 Mar 2023 //
GLOBENEWSWIRE
BeyondSpring Enrolls First Patient in Ph2 Study Plinabulin, Keytruda & Docetaxel
01 Mar 2023 //
GLOBENEWSWIRE
Alembic Pharma gets USFDA nod to market generic cancer drug
01 Mar 2023 //
ECONOMIC TIMES
Positive CHMP opinion for darolutamide in combination with docetaxel for mHSPC
27 Jan 2023 //
GLOBENEWSWIRE
BeyondSpring Presents Data with Plinabulin for Docetaxel-Induced Neutropenia
13 Dec 2022 //
GLOBENEWSWIRE
Exelixis/Roche Combo Fails to Improve Overall Survival in NSCLC
10 Dec 2022 //
BIOSPACE
Lyvgen and BMS partner for Phase II lung cancer antibody trial
28 Nov 2022 //
CLINICALTRIALSARENA
Chemotherapy may be completed within 8 days with two doses of Polytaxel
25 Nov 2022 //
PRNEWSWIRE
Health Canada approves additional indication for NUBEQA® (darolutamide)
05 Oct 2022 //
BAYER
NanOlogy Publishes Review Article of Clinical Research Supporting LSAM-DTX
20 Sep 2022 //
BUSINESSWIRE
New ARASENS data reinforce strong tolerability profile of darolutamide
11 Sep 2022 //
PRESS RELEASE
Lumakras Demonstrates Progression-Free Survival Over Docetaxel
11 Sep 2022 //
PRNEWSWIRE
Bayer`s Nubeqa nabbed a second prostate cancer indication
09 Aug 2022 //
FIERCEPHARMA
U.S. FDA approves additional indication of darolutamide + docetaxel
08 Aug 2022 //
GLOBENEWSWIRE
U.S. FDA Approves Additional Indication of NUBEQA in Combination with Docetaxel
05 Aug 2022 //
BUSINESSWIRE
Merck Provides Update on Phase 3 KEYNOTE-921
03 Aug 2022 //
BUSINESSWIRE
Arcus Biosciences Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Docetaxel
01 Aug 2022 //
BUSINESSWIRE
Darolutamide plus androgen deprivation therapy & docetaxel demonstrate OS benefits
04 Jul 2022 //
PRESS RELEASE
NeoTX successfully completes 1st stage of PIIa trial of NAP+docetaxel in NSCLC
01 Jun 2022 //
PRNEWSWIRE
Akeso Announces IND Approval from China NMPA for Phase II Trial of Cadonilimab
07 Mar 2022 //
PRNEWSWIRE
Update on SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar
22 Feb 2022 //
GLOBENEWSWIRE
LIDDS Next Step with NanoZolid formulated docetaxel
21 Feb 2022 //
GLOBENEWSWIRE
Trial results deliver hope for prostate cancer patients
18 Feb 2022 //
PHARMATIMES
Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r
17 Feb 2022 //
BUSINESSWIRE
Results from Phase III Show NUBEQA + ADT and Docetaxel Increases OS in mHSPC
17 Feb 2022 //
BUSINESSWIRE
Appeals court quashes Sanofi’s big win on bellwether hair loss case
12 Feb 2022 //
ENDPTS
Bayer`s Nubeqa triumphs in metastatic prostate cancer
04 Dec 2021 //
FIERCEPHARMA
ARASENS Phase III trial for prostate cancer treatment meets primary endpoint
03 Dec 2021 //
PHARMAFILE
ARASENS trial with darolutamide in combination with docetaxel and androgen
02 Dec 2021 //
GLOBENEWSWIRE
Nivoluma plus docetaxel in patients with chemotherapy-naïve metastatic
26 Nov 2021 //
FIRSTWORDPHARMA
Sanofi Wins Second Test Trial in Taxotere Cancer Drug Litigation
23 Nov 2021 //
BLOOMBERGLAW
Esmo 2021 – Beyondspring experiences winter of discontent
21 Sep 2021 //
EVALUATE
BeyondSpring Pharma Announces Positive Final Phase 3 DUBLIN-3 Data at ESMO21
20 Sep 2021 //
GLOBENEWSWIRE
Gland Pharma`s Generic Docetaxel Receives Approval In US
05 Jul 2021 //
FDA
Enforcement Report - Week of December 16, 2020
16 Dec 2020 //
FDA
Popular chemotherapy drug may be less effective in overweight and obese women
03 Jul 2020 //
MEDICALXPRESS
Oasmia AB Signs Phase 1b Trial Agreement with SAKK, The Swiss Group
08 Jun 2020 //
PRESS RELEASE
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer
08 Jun 2020 //
PRNASIA
